A double blind clinical trial of Iloprost during cardiopulmonary bypass
| Autor: | JV Arnold, Kenneth M. Taylor, C. Blauth, WE Schulenburg, A. Brady, R. Frackowiak, J.J. Brannan |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
medicine.medical_specialty
Prostacyclin 030204 cardiovascular system & hematology Placebo law.invention 03 medical and health sciences 0302 clinical medicine Bleeding time Platelet preservation law Internal medicine medicine Cardiopulmonary bypass Radiology Nuclear Medicine and imaging Advanced and Specialized Nursing medicine.diagnostic_test business.industry General Medicine Clinical trial 030228 respiratory system Cardiology Arterial line Cardiology and Cardiovascular Medicine business Safety Research circulatory and respiratory physiology Iloprost medicine.drug |
| Zdroj: | Perfusion. 2:271-276 |
| ISSN: | 1477-111X 0267-6591 |
| DOI: | 10.1177/026765918700200405 |
| Popis: | Twenty patients undergoing elective coronary surgery were randomized to receive either the prostacyclin analogue Iloprost (Zk 36374) 5 ng/kg/min for 30 minutes before cardiopulmonary bypass (CPB) increasing to 10 ng/kg/min during CPB, or placebo, to investigate any beneficial effect on platelet preservation, or protection of the central nervous system during clinical CPB. Originally 50 patients were to have entered the trial, but unacceptable hypotensive effects occu rred in five patients who received Iloprost, lead i ng to early data analysis. No significant improvement in platelet number, volume or function; bleeding time; arterial line filter δ dry weight; retinal microembolism; or neuropsychological function, attributable to Iloprost, could be identified. The role and optimal dose of Iloprost in clinical CPB remains to be established. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|